OncoMatch/Clinical Trials/NCT06692166
A Study to Evaluate 9MW2821 Versus Treatment of Physician's Choice for Subjects With Recurrent or Metastatic Cervical Cancer
Is NCT06692166 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including 9MW2821 and Chemotherapy for cervical cancer.
Treatment: 9MW2821 · Chemotherapy — The purpose of this study is to compare the efficacy and safety of 9MW2821 and chemotherapy in participants with recurrent or metastatic cervical cancer who progressed on or after platinum-based chemotherapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Cervical Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: platinum-based chemotherapy
Subject must have received a platinum-based chemotherapy with or without bevacizumab and received no more than 2 prior systemic therapy in the metastatic/recurrent setting. Subject must have experienced radiographic progression during or after the last treatment regimen.
Cannot have received: nectin-4 targeted antibody-drug conjugate
received treatment of nectin-4 targeted ADC
Cannot have received: antibody-drug conjugate with MMAE payload
received treatment of ADC with MMAE payload
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify